Optimizing Clinical Trials In China With Strategic Solutions For Supply Chain Challenges

By Catalent Experts

hina has rapidly emerged as a key hub for global clinical trials, supported by its large and diverse patient population, expanding pharmaceutical market, and increasingly advanced healthcare infrastructure. As a result, the country is playing a growing role in multinational clinical research programs. However, conducting trials in China also requires careful navigation of a complex and evolving regulatory and logistical environment.

The regulatory framework continues to evolve as authorities work to align with international standards and improve approval efficiency. The National Medical Products Administration (NMPA) has introduced several initiatives to strengthen drug quality, safety, and oversight, including the Marketing Authorization Holder system (MAH). Under this system, the MAH is responsible for the full lifecycle of a product—from research and development through manufacturing and post-marketing surveillance. The NMPA also requires robust drug traceability and pharmacovigilance systems to monitor and report adverse events.

To further support innovation, the NMPA has launched a pilot program that aims to accelerate approvals for innovative drug clinical trials, targeting a review timeline of approximately 30 working days. This initiative reflects China’s commitment to strengthening its clinical trial ecosystem while maintaining high standards for safety and quality.

In parallel, strict importation requirements for clinical trial materials can create logistical challenges. Strategic use of Free Trade Zones (FTZs) can help address these hurdles by offering streamlined customs procedures and potential tax advantages. Sponsors planning clinical trials in China should carefully consider these regulatory and logistical factors, including the use of FTZs, to help minimize delays and ensure efficient study execution.